Abstracts tagged "race/ethnicity"

Abstract Number: 0188 • ACR Convergence 2024
Social Support in African American Women with and Without Systemic Lupus Erythematosus (SLE)
Sarah Smith¹, Chloe Mattila¹, Charmayne M. Dunlop-Thomas², Lusawasra King³, Lori Ann Ueberroth³, Edith Williams⁴, S. Sam Lim⁵, Diane Kamen³, Bethany Wolf³ and Paula Ramos³, ¹Medical University of South Carolina, Charleston, ²Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ³Medical University of South Carolina, Charleston, SC, ⁴University of Rochester School of Medicine and Dentistry, Rochester, ⁵Emory University, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately impacts African American women. However, this health disparity population continues to be underrepresented in research. Research suggests that social…
Abstract Number: 1143 • ACR Convergence 2024
Epidemiology and Spectrum of Idiopathic Inflammatory Myopathies in Individuals of Sub-Saharan Ancestry: Data from the Tertiary Care Center of the Caribbean Island of Martinique
Benoit Suzon¹, Rachel Robert¹, Fabienne Louis-sidney², Arthur Felix¹, Illitch Coco-Viloin¹, Florence Moinet³, Rodolphe Cougnaud¹, Rémi Bellance¹, Emmanuelle Amazan¹, Emma pierrisnard¹, Moustapha Agossou¹, Christophe Deligny⁴ and Aurore Abel¹, ¹University Hospital of Martinique, Fort-de-France, Martinique, ²University Hospital Martinique, Fort De France, Martinique, ³University Hospital of Martinique, Fort de France, France, ⁴University Hospital of Martinique - National reference center for autoimmune disease, Internal Medicine, Fort-de-France, Martinique
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are heterogeneous systemic autoimmune diseases with a worldwide incidence ranging from 0.116 to 1.9 and a prevalence from 2.4 to…
Abstract Number: 2447 • ACR Convergence 2024
Features of Anti-Fibrillarin Positive Systemic Sclerosis Patients and Ethnic Differences: A European Multicenter Cohort
Roberto D'Alessandro¹, Stefano Rodolfi², Alix Calot¹, Louis Bébéar³, Corrado Campochiaro⁴, Veronica Codullo⁵, Francesco Del Galdo⁶, Ivan Castellvi Barranco⁷, Elisabetta Zanatta⁸, Silvia Bellando Randone⁹, Goncalo Boleto¹⁰, Loic Raffray¹¹, Emmanuel Chatelus¹², Patrice Cacoub¹³, Alexandre Le Joncour¹³, Paolo Airò¹⁴, cristiana sieiro santos¹⁵, Alain Lescoat¹⁶, Jérôme Avouac¹⁷, Christopher Denton¹⁸ and Yannick Allanore¹⁹, ¹Rheumatology Department, Cochin Hospital, Université Paris Cité, APHP, Paris, France, Paris, France, ²Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, UK, London, United Kingdom, ³Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, France., Bordeaux, France, ⁴IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ⁵Division of Rheumatology - Policlinico San Matteo, Pavia, Italy, Pavia, Lombardia, Italy, ⁶University of Leeds, Leeds, United Kingdom, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁸Unit of Rheumatology, Padova University, Padova, Italy, ⁹Department of Experimental and Clinical Medicine University of Florence Division of Rheumatology Scleroderma Unit, Careggi Hospital Florence, Italy, Florence, Toscana, Italy, ¹⁰Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal., Lisbon, Portugal, ¹¹CHU La Réunion - Competence center for autoimmune diseases, Internal Medicine, Saint-Denis, Reunion, ¹²Rheumatology department strasbourg, Strasbourg, France, ¹³Department of Internal Medicine and Clinical Immunology France, Centre national de référence maladies Autoimmunes Systémiques rares, Centre national de référence maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Pitié Salpetrière, 75013 Paris, France, Paris, France, ¹⁴Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ¹⁵Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ¹⁶Department of Internal Medicine and Clinical Immunology, Rennes University Hospital, Rennes, France, rennes, France, ¹⁷Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ¹⁸University College London, Northwood, United Kingdom, ¹⁹Rheumatology department, Université Paris Cité, Cochin Hospital of Paris; France, Paris, France
Background/Purpose: Anti-fibrillarin (AFA) auto-antibodies are rarely found in Systemic Sclerosis (SSc). Beyond the ethnic association with a higher prevalence in patients of Black ethnicity, the…
Abstract Number: 0189 • ACR Convergence 2024
Racial Discrimination Among African American Women with and Without Systemic Lupus Erythematosus (SLE)
Jessica Browder¹, Paula Ramos², Diane Kamen², Bethany Wolf², S. Sam Lim³, Lori Ann Ueberroth² and Lusawasra King², ¹Florida State University, Tallahassee, FL, ²Medical University of South Carolina, Charleston, SC, ³Emory University, Atlanta, GA
Background/Purpose: Black or African American women are disproportionately affected by SLE but remain underrepresented in research studies. To further knowledge about this health disparity group,…
Abstract Number: 1285 • ACR Convergence 2024
The Impact of Race and Social Determinants of Health on Patient Reported Outcomes in Pediatric Lupus: A CARRA Registry Study
William Soulsby¹, Rebecca Olveda², Jie He³, Laura Berbert⁴, Edie Weller³, Kamil Barbour⁵, Kurt Greenlund⁵, Laura Schanberg⁶, Emily Von Scheven¹, Aimee Hersh⁷, Mary Beth Son⁸, Joyce Chang⁸ and Andrea Knight⁹, and the CARRA Registry Investigators, ¹University of California, San Francisco, San Francisco, CA, ²Palo Alto Medical Foundation, Dublin, CA, ³Boston Children's Hospital, Boston, MA, ⁴Boston Children's Hospital, Belmont, MA, ⁵CDC, Alpharetta, GA, ⁶Duke University Medical Center, DURHAM, NC, ⁷University of Utah, Salt Lake City, UT, ⁸Boston Children's Hospital, Brookline, MA, ⁹Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Minoritized race and social determinants of health (SDoH) are associated with lower achievement of the low lupus disease activity state (LLDAS) and higher cumulative…
Abstract Number: 2454 • ACR Convergence 2024
Age-Adjusted Mortality Rate Trends in Systemic Sclerosis in the United States from 1999 to 2020
Ansaam Daoud¹, Loai Dweik², Muhammad Shamim³, Haseeb Chaudhary⁴ and Omer Pamuk⁵, ¹Case Western Reserve University/University Hospitals, Akron, OH, ²Cleveland Clinic Akron General Internal Medicine, Akron, OH, ³University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ⁴Case Western Reserve University, Westlake, OH, ⁵University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Of all rheumatic diseases, systemic sclerosis (SSc) has the highest disease-specific mortality, with a higher mortality risk than the general population. North America has…
Abstract Number: 0191 • ACR Convergence 2024
Beyond the Symptoms: Exploring Cognitive Bias in Lupus Diagnosis Within Primary Care
Alyssa Howren¹, Quan Le Tran¹, Sadaf Sediqi¹, Saadiya Hawa², Eleni Linos¹, Titilola Falasinnu³, Yashaar Chaichian¹ and Julia Simard¹, ¹Stanford School of Medicine, Stanford, CA, ²Weiss Memorial Hospital, Chicago, IL, ³Stanford School of Medicine, Palo Alto, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune rheumatic disease whose prognosis varies by race and sex. To understand whether the cognitive processes of…
Abstract Number: 1286 • ACR Convergence 2024
An Analysis of Diversity, Equity, and Inclusion Initiatives in US ACGME-accredited Adult Rheumatology Fellowship Programs
Hamza Ali and Alysia Kwiatkowski, University at Buffalo, Buffalo, NY
Background/Purpose: The ACR 2015 Workforce Study Report highlighted a lack of diversity within the workforce with 73.6% of Adult Rheumatology providers identifying as White, 15%…
Abstract Number: 2553 • ACR Convergence 2024
Predictors of Biologic and Targeted Synthetic DMARD Initiation for Rheumatoid Arthritis Across Underserved Patient Groups: Insights from a National Cohort Study
Mark Russell¹, Mark Gibson², Benjamin Zuckerman¹, Kanta Kumar³, Shirish Dubey⁴, Maryam Adas², Edward Alveyn², Samir Patel¹, Zijing Yang¹, Katie Bechman², Elizabeth Price⁵, Sarah Gallagher⁶, Andrew Cope², Sam Norton¹ and James Galloway⁷, ¹King's College London, London, England, United Kingdom, ²King's College London, London, United Kingdom, ³University of Birmingham, Birmingham, United Kingdom, ⁴Oxford University Hospitals NHS FT, Oxford, United Kingdom, ⁵Great Western Hospital NHS Foundation Trust, Swindon, England, United Kingdom, ⁶British Society for Rheumatology, London, United Kingdom, ⁷Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Quantifying healthcare inequality is essential to addressing the imbalance in outcomes attributable to age, gender, ethnicity and multimorbidity. In this study, we analysed differences…
Abstract Number: 0196 • ACR Convergence 2024
Associations Between Systemic Lupus Erythematosus (SLE) and the Social Vulnerability Index (SVI)
Zoe Reed¹, Xana Howard¹, Cristina Arriens¹, Teresa Aberle¹, Wade DeJager², Joan Merrill³ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that disproportionately affects young women of certain racial and ethnic minority groups with enhanced severity…
Abstract Number: 1337 • ACR Convergence 2024
Gender and Ethnic Differences (or Lack Thereof) in Perceived Disease Burden in RA
Ali Malik¹, Dennis Ang¹, Adam Hall¹, John Herion¹ and Rupak Thapa², ¹Wake Forest University, Winston Salem, NC, ²Assistant Professor, Winston Salem, NC
Background/Purpose: Gender and ethnic disparities in health care are well reported in the general medical literature. Differences in symptom reporting or perceived health status can…
Abstract Number: 2589 • ACR Convergence 2024
A Nationwide Analysis of Risk of Acute Coronary Syndrome in RA Patients with Interstitial Lung Disease
Omair Khan¹, Azka Naeem², Kundan Jana², Syed Mujtaba Baqir², Tharun Shyam² and Saumya Nanda², ¹Maimonides Medical Center, Council Bluffs, IA, ²Maimonides Medical Center, Brooklyn, NY
Background/Purpose: Rheumatoid Arthritis (RA) and Interstitial Lung Disease (ILD) are systemic inflammatory conditions that independently increase the risk of Acute Coronary Syndrome (ACS). However, there…
Abstract Number: 0210 • ACR Convergence 2024
Rheumatology, Heal Thyself: The Experience of Underrepresented Physicians in Rheumatology
Rob Valdovinos¹, Ashley Martin², Jay Mehta² and Irene Blanco³, ¹UCSF Benioff Children's Hospital, San Francisco, CA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Northwestern University, Oak Park, IL
Background/Purpose: Providing racially and ethnically concordant care in minoritized populations by providers identifying as underrepresented in medicine (URiM) has been reported to be associated with…
Abstract Number: 1404 • ACR Convergence 2024
Modeling Diversity in Systemic Lupus Erythematosus (SLE) Clinical Trials Using Real-world Data (RWD) Sources
Andrew Bevan¹ and Nora Carroll², ¹Integrated Project Solutions, PPD, part of Thermo Fisher Scientific, Cambridge, United Kingdom, ²Cardiovascular and General Medicine, Thermo Fisher Scientific, Athlone, Ireland
Background/Purpose: The FDA places emphasis on studying clinically relevant trial populations but does not address how these might be defined. SLE disproportionately affects women and…
Abstract Number: PP12 • ACR Convergence 2024
Healing Together: The Role of Black, Indigenous and People of Color (BIPOC) -Only Chronic Illness Spaces in Comprehensive Care
Sarah Shaw and JP Summers, Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose: As someone from the Black, Indigenous, and People of Color (BIPOC) community living with rheumatic conditions, I have experienced firsthand many challenges that people…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.